L-Ergothioneine for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

L-Ergothioneine for Health & Longevity

Created on 08/28/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A compound the body cannot make and takes up through a carrier apparently built for it alone. Levels fall with age and are lower in people whose health is declining. Higher blood levels travel with lower risk of heart disease, death and dementia. Supplement trials are few, small and short, several company-funded. Safety is the least contested part. (Full Review)

Protocol

Standard supplement dose
5–25 mg daily
Range used in controlled trials; sleep benefit at 8 mg, cognitive and skin trials at 25 mg
Food-first alternative
100 g mushrooms daily
Oyster, king oyster, shiitake and porcini are the richest common species; approaches trial-level intakes
Single versus split dosing
Single daily dose
Long half-life and saturable transporter uptake mean splitting offers no advantage; divided dosing untested
Time to effect
Cognitive measures
1 year
Verbal learning improved and the nerve-damage marker held steady over a full year of dosing
Sleep quality
16 weeks
Self-rated sleep quality; blood levels rise within days and plateau over 4–8 weeks
Skin moisture
8 weeks
Wrinkle and texture scores followed at 12 weeks in the same trial

Benefits

Contraindications
  • People receiving pro-oxidant anticancer treatment (anthracyclines, platinum drugs, radiotherapy) until the treating oncologist has reviewed the supplement
  • Documented mushroom allergy, where the product is whole-mushroom powder or extract rather than purified L-ergothioneine
Key Interactions
  • Transporter-substrate medicines (gabapentin, verapamil, quinidine, oxaliplatin): caution, low-grade
  • Other antioxidant supplements (N-acetylcysteine, alpha-lipoic acid, high-dose vitamin C or E): caution, additive
  • L-carnitine and related zwitterions: monitor only
  • Over-the-counter analgesics and antacids: no interaction identified

Risk & Side Effects

  • Low: Flagellate dermatitis from shiitake-containing products; trimethylamine N-oxide generation by gut bacteria (conflicted); competition at the OCTN1 transporter with co-administered drugs
  • Speculative: Support of tumour-cell antioxidant defences; blunting of exercise training adaptations

Monitoring

Marker Target Why
Plasma or whole-blood L-ergothioneine No established target; track change from own baseline Confirms absorption and whether a person was depleted to begin with
hs-CRP Under 1.0 mg/L Tracks the body-wide inflammatory tone the compound is proposed to lower
CBC Haemoglobin and red cell indices within laboratory reference; no fall from baseline Red blood cells hold the largest tissue pool; the safety panel the trials monitored
ALT 10–26 U/L men, 7–20 U/L women Standard safety check for any long-term supplement
eGFR Above 90 mL/min/1.73 m² The kidney reclaims L-ergothioneine, so kidney function shapes how much is retained
Plasma NfL No established target; change from own baseline over 6–12 months The cognitive trial's objective marker of ongoing nerve-cell damage
TMAO Below roughly 6 µmol/L Addresses the one mechanistic objection raised against supplementation

Cadence: Baseline before starting; L-ergothioneine level repeated at 8–12 weeks; inflammation and safety panels rechecked at 6 months; annually thereafter.

Qualitative Assessment

  • Sleep quality and ease of falling asleep, tracked with a consistent weekly self-rating rather than impressions
  • Daytime energy and perceived recovery from training
  • Memory and word-finding in ordinary conversation, particularly noticed by people who know the individual well
  • Skin hydration and texture, most apparent on the forearm and temple after two to three months
  • Absence of digestive upset, rash or any new symptom after starting
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.